The near-term PDUFA date (July 29, 2026) creates a binary catalyst. Traders should position for potential approval-driven upside, but also hedge against the risk of a Complete Response Letter. Monitor any FDA advisory committee announcements or pre-PDUFA updates.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 16 $1.57entry
- T+1 · 5mo ago +5.10%α +6.34% · $1.65
- T+5 · 5mo ago +8.28%α +10.51% · $1.70
- T+20 · 4mo ago +10.19%α +9.99% · $1.73
- T+60 · 2mo ago −57.89%α −58.88% · $0.6612
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) to treat wet AMD. The FDA classified the resubmission as a Class 1 review with a 60-day review period, setting a PDUFA goal date of July 29, 2026. This moves the company one step closer to potential U.S. approval for its ophthalmic bevacizumab formulation, which already has marketing authorization in the EU and UK.
Key Facts
- FDA accepted resubmitted BLA for ONS-5010 (bevacizumab-vikg) for wet AMD
- Class 1 review with 60-day review period
- PDUFA goal date set for July 29, 2026
- ONS-5010/LYTENAVA already approved in EU and UK for wet AMD
- Company has initiated pre-launch activities in anticipation of potential FDA approval
Financial Impact
Potential U.S. approval would open a large market for the first FDA-approved ophthalmic bevacizumab formulation; no financial figures provided in filing.
Risk Factors
- FDA may issue a Complete Response Letter despite Class 1 review status
- Competition from existing anti-VEGF therapies (Eylea, Lucentis, Vabysmo)
- Pricing and reimbursement uncertainties in the U.S. market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074346 |
| Document: tm2618010d1_ex99-1.htm | 0001104659-26-074346 |
| Document: 0001104659-26-074346-index-headers.html | 0001104659-26-074346 |
| Document: 0001104659-26-074346-index.html | 0001104659-26-074346 |
| Document: 0001104659-26-074346.txt | 0001104659-26-074346 |
Track record
37 reports on OTLK
12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers